Market Research Logo

Anterior Uveitis - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Anterior Uveitis Overview
Therapeutics Development
Pipeline Products for Anterior Uveitis - Overview
Anterior Uveitis - Therapeutics under Development by Companies
Anterior Uveitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anterior Uveitis - Products under Development by Companies
Anterior Uveitis - Companies Involved in Therapeutics Development
Aciont Inc.
Aldeyra Therapeutics, Inc.
EyeGate Pharmaceuticals, Inc.
KPI Therapeutics, Inc.
Neuroptis Biotech
Anterior Uveitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LME-636 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anterior Uveitis - Dormant Projects
Anterior Uveitis - Discontinued Products
Anterior Uveitis - Product Development Milestones
Featured News & Press Releases
May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis
Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial
Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial
Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program
Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis
Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anterior Uveitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Anterior Uveitis - Pipeline by Aciont Inc., H2 2016
Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016
Anterior Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016
Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Anterior Uveitis - Dormant Projects, H2 2016
Anterior Uveitis - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Anterior Uveitis, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Anterior Uveitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Anterior Uveitis - Pipeline Review, H2 2016’, provides an overview of the Anterior Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
    • The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
    • The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Anterior Uveitis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report

    ;